A computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy

被引:38
作者
Engel, C [1 ]
Scholz, M [1 ]
Loeffler, M [1 ]
机构
[1] Univ Leipzig, IMISE, D-04103 Leipzig, Germany
关键词
D O I
10.1182/blood-2004-01-0306
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Moderate intensification of conventional multicycle chemotherapy has recently been shown to improve treatment results in malignant lymphomas and might prove to be beneficial also in other malignancies. However, the feasibility of such regimens is mainly limited by their granulopoietic toxicity. To identify and quantify the basic cell kinetic mechanisms of damage and stimulation caused by cytotoxic drugs and recombinant human granulocyte colony-stimulating factor (rhG-CSF), respectively, we developed a mathematical model of human granulopoiesis that allows simulation of leukocyte concentration profiles under 10 different multicycle polychemotherapy regimens with varying drug composition, dosage, and scheduling, including rhG-CSF assistance. Clinical data on leukocyte profiles were obtained from large numbers of patients treated within several multicenter trials. Simulation studies show that the leukocyte profiles of all regimens can be appropriately fitted using one single set of assumptions and parameters for the cell kinetic effects of cytotoxic drugs and rhG-CSF. Furthermore, the model can be used to explain the interindividual heterogeneity of hematotoxicity by a differential chemosensitivity, which might be useful in drug scheduling for specific risk groups. It is demonstrated that the model can be used to design and to select new drug schedules for subsequent clinical trial testing. (C) 2004 by The American Society of Hematology.
引用
收藏
页码:2323 / 2331
页数:9
相关论文
共 58 条
[51]   Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy:: A study of the German Hodgkin's Lymphoma Study Group [J].
Tesch, H ;
Diehl, V ;
Lathan, B ;
Hasenclever, D ;
Sieber, M ;
Rüffer, U ;
Engert, A ;
Franklin, J ;
Pfreundschuh, M ;
Schalk, KP ;
Schwieder, G ;
Wulf, G ;
Dölken, G ;
Worst, P ;
Koch, P ;
Schmitz, N ;
Bruntsch, U ;
Tirier, C ;
Müller, U ;
Loeffler, M .
BLOOD, 1998, 92 (12) :4560-4567
[52]   RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR REDUCES THE INFECTIOUS COMPLICATIONS OF CYTOTOXIC CHEMOTHERAPY [J].
TRILLETLENOIR, V ;
GREEN, J ;
MANEGOLD, C ;
VONPAWEL, J ;
GATZEMEIER, U ;
LEBEAU, B ;
DEPIERRE, A ;
JOHNSON, P ;
DECOSTER, G ;
TOMITA, D ;
EWEN, C .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (03) :319-324
[53]  
Watari K, 1997, INT J HEMATOL, V66, P57
[54]   Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSP in healthy volunteers [J].
Watts, MJ ;
Addison, I ;
Long, SG ;
Hartley, S ;
Warrington, S ;
Boyce, M ;
Linch, DC .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (02) :474-479
[55]  
Wichmann H. E., 1985, MATH MODELING CELL P
[56]  
WICHMANN HE, 1988, BLOOD CELLS, V14, P411
[57]  
WINTROBE MM, 1974, WINTROBES CLIN HEMAT
[58]   Practicability and acute haematological toxicity of 2-and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) [J].
Wunderlich, A ;
Kloess, M ;
Reiser, M ;
Rudolph, C ;
Truemper, L ;
Bittner, S ;
Schmalenberg, H ;
Schmits, R ;
Pfreundschuh, M ;
Loeffler, M .
ANNALS OF ONCOLOGY, 2003, 14 (06) :881-893